Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT03627728 Recruiting - Gastric Cancer Clinical Trials

Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

a-MANTRA
Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, multicenter Phase-II study. Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the following treatment groups: Arm A: Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease Arm B: Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease Primary Variable: PFS1

NCT ID: NCT03623464 Recruiting - Pancreatic Cancer Clinical Trials

RCT of Mobile Apps & FitBit v. Usual Care

Start date: May 31, 2017
Phase: N/A
Study type: Interventional

This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in geriatric patients undergoing major GI cancer operations.

NCT ID: NCT03621982 Not yet recruiting - Ovarian Cancer Clinical Trials

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Start date: August 2, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

NCT ID: NCT03620643 Not yet recruiting - Gastric Cancer Clinical Trials

ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

ROLo
Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer tumours. The investigators will also be assessing the side effects of the combination of crizotinib tablets and fulvestrant injections. The side effects and the doses of crizotinib and fulvestrant have already been evaluated in large clinical trials, but this is the first time these two drugs will be combined together.

NCT ID: NCT03619681 Not yet recruiting - Breast Cancer Clinical Trials

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Start date: August 31, 2018
Phase: Phase 1
Study type: Interventional

This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation. There are 4 proposed dose levels which are 5, 10, 15, and 20 mg/kg, but dosing interval may be adjusted during the study (such as QW, OR Q2W, OR Q3W) based on emerging data from this trial and/or from phase 1 trial of KN026 in other country. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or if MTD is not found, dose escalation will continue until the MAD of 20 mg / kg is reached.

NCT ID: NCT03613142 Not yet recruiting - Gastric Cancer Clinical Trials

Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The patients with upper gastric cancer (cT1N0M0) or gastroesophageal adenocarcinoma (diameter less than 4 cm) will be enrolled into this study. Each of these patients will undergo radical proximal gastrectomy and be randomly allocated into one of the two groups, double tract anastomosis group or esophagogastrostomy group. The following data will be collected to compare the difference between the two reconstruction methods: the rate of reflux esophagitis, postoperative quality of life, economic expenditure, the safety of operation, postoperative recovery, postoperative nutrition status and oncological effect. Through the comprehensive analysis, the result of this study will elucidate the best of the reconstruction method after proximal gastrectomy.

NCT ID: NCT03609892 Not yet recruiting - Gastric Cancer Clinical Trials

Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This study aims at evaluating efficacy and safety of berberine- amoxicillin containing quadruple therapy(berberine, amoxicillin, esomeprazole and bismuth) versus tetracycline-furazolidone quadruple therapy (tetracycline, furazolidone, esomeprazole and bismuth) in H. pylori rescue therapy. It is hypothesized that berberine-amoxicillin containing quadruple therapy is non-inferior to tetracycline-furazolidone quadruple therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test´╝îrapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.

NCT ID: NCT03606928 Recruiting - Gastric Cancer Clinical Trials

mFLOT Chemotherapy as First-line Treatment in GC

Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A single center phase 1b/2 trail to identified suitable dosage and its efficacy of modified FLOT regime in Chinese gastric cancer patients. This trial is designed to identified recommended phase II dose (RP2D) of modified FLOT in Chinese patients, and to evaluate the efficacy of modified FLOT regime as first-line for advanced or metastatic gastric cancer. This trial is in 2 stages: the first stage will establish the maximum tolerated dose (MTD) and RP2D of docetaxel and oxaliplatin in FLOT regime. In the second stage, the efficacy of modified FLOT will be assessed by response rate.

NCT ID: NCT03601988 Recruiting - Gastric Cancer Clinical Trials

Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer

Start date: July 28, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected gastric cancer

NCT ID: NCT03598348 Recruiting - Gastric Cancer Clinical Trials

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Start date: January 16, 2018
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after First-line XELOX/SOX chemotherapy for Patients with Advanced Gastric Cancer